{"groups":[{"description":"ARM I: Patients receive 3 doses of tetanus before transplant and on days 15, and 60 post transplant.\n\nMelphalan: Given IV\n\nPeripheral Blood Stem Cell Transplantation--CD34 HSCT: Undergo autologous CD34 HSCT\n\nPeripheral Blood Stem Cell Transplantation--AHSCT: Undergo AHSCT\n\nT Cell-Depleted Hematopoietic Stem Cell Transplantation: Undergo autologous CD34 HSCT\n\nTetanus Toxoid Vaccine: Given IM","id":"FG000","title":"Arm I (Vaccine, CD34 Transplant, DLI)"},{"description":"Patients receive 3 doses of tetanus as in Arm I. Patients receive high-dose melphalan IV on day -2 and undergo AHSCT on day 0.\n\nMelphalan: Given IV\n\nPeripheral Blood Stem Cell Transplantation--AHSCT: Undergo AHSCT\n\nTetanus Toxoid Vaccine: Given IM","id":"FG001","title":"Arm II (Vaccine, Stem Cell Transplant)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}